drugset / Trial / NCT02706483

Long Term Safety Study of Plecanatide

NCT02706483

Phase 3 Completed 2272 enrolled Bausch Health Americas, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Multi-center, open-label, long-term safety study

Timeline

Start
2016-01
Primary completion
2017-05
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Plecanatide Peptide 6 mg Oral